Media Coverage

Genome Web: Mt. Sinai Studying CTCs, ctDNA in Context of Triple Negative Breast Cancer

April 1, 2016 - Genome web article highlighting a trial by researchers at Mount Sinai to evaluate the genomic profiles of ctDNA and CTCs as well as phenotypic features of CTCs in patients with triple negative breast cancer to study the relationships between the two and how they correlate with disease. The group will use Cynvenio's LiquidBiopsy microfluidic system to isolate CTCs, ctDNA, and germline DNA.

GenomeWeb: Companies Increasingly Aim to Tap into Growing Liquid Biopsy Market

Jan. 26, 2015 - With evidence building that monitoring a tumor's mutational landscape can be done by evaluating circulating tumor DNA or circulating tumor cells, companies are increasingly looking to move into the liquid biopsy market. Over the last month, the larger players in cancer genomics have all announced their intentions to get into the market, as well.  

The ASCO Post: Potential of Liquid Biopsies in Detecting Cancer and Establishing Prognosis

September 15, 2014 - The ASCO Post talked with Dr. ­Cristofanilli, a member of Cynvenio's clinical advisory board, about the accuracy of liquid biopsies in detecting and analyzing cancer, their potential use as a tool for cancer screening in healthy people, and how they can provide accurate prognostic information in patients with recurrent disease.

GenomeWeb: Cynvenio Looks to Add Cell-free DNA Analysis to Circulating Tumor Cell Platform

Sept. 10, 2014 - In this Clinical Sequencing News article published by GenomeWeb, Paul Dempsey, Ph.D., Cynvenio’s CSO, is interviewed about the company’s research and activities to establish the utility of cell-free DNA relative to, and potentially in combination with CTC analysis.   [Premium Subscriber Content]